Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group.
Sonsoles Berenguer-RuizMario Aparicio-DomínguezPedro Herranz-PintoRicardo Ruíz-VillaverdeAnna López-FerrerJorge Santos-JuanesLourdes Rodríguez Fernández-FreireMercedes Hospital-GilSalvador Arias-SantiagoGregorio Carretero-HernándezAlmudena Mateu-PuchadesMarta FerranElena Del Alcázar-ViladomiuSergio Santos-AlarcónFrancisco Javier Garcia-Latasa de AranibarIsabel Belinchón-RomeroAlvaro Gonzalez-CanteroDiana P Ruiz GenaoNoemí Eiris-SalvadoVicenç Rocamora-DuránRaquel Rivera-DíazPablo de la Cueva-DobaoEsteban DaudénLaura Salgado-BoqueteMar Llamas Velasconull nullPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Tildrakizumab was effective and safe in a large cohort of patients with moderate-to-severe plaque psoriasis treated in a routine clinical setting.